Table 1.

Baseline characteristics of all randomized patients

	Group C (ribavirin 800 mg)	Group D (ribavirin 400 mg)	All patients
n	31	51	82
Age, years ± SD	36.6 ± 11.0	34.9 ± 9.9	35.5 ± 10.3
Sex, male/female	13/18	21/30	34/48
Mean baseline HCV RNA (Mio. IU/mL) ± SD	1.447 ± 2.93	0.869 ± 1.46	1.083 ± 2.13
Mean Body weight (kg) ± SD	74.2 ± 18.8	68.7 ± 13.9	70.8 ± 16.0
Mean BMI ± SD	24.5 ± 5.7	23.3 ± 3.6
Means by which HCV was acquired, n (%)
Blood transfusion	3 (9.7)	6 (11.8)	9 (11)
Intravenous drug use	20 (64.5)	28 (54.9)	48 (58.5)
Other	3 (9.7)	2 (3.9)	5 (6.1)
Unknown	5 (16.1)	15 (29.4)	20 (24.4)